Some folks’s genes affect how a lot weight they are going to lose and what negative effects they are going to expertise whereas taking GLP-1 medicine, resembling Ozempic and Zepbound.
The genetic testing firm 23andMe carried out a examine of greater than 27,000 clients who had been taking GLP-1 medicine. Such medicine work by mimicking the motion of GLP-1, a hormone that helps regulate blood sugar and urge for food. Individuals who carry a selected genetic variant of the GLP-1 receptor gene GLP1R misplaced extra weight than those that don’t carry that variant, researchers report April 8 in Nature.
“The outcomes that we bought made excellent organic sense,” says statistical geneticist Adam Auton, vice chairman of human genetics on the 23andMe Analysis Institute in Palo Alto, Calif. That’s as a result of the receptor is the goal of GLP-1 mimicking medicine. The variant the researchers discovered might improve the quantity of the receptor protein on the cell floor, giving the drug extra targets, Auton says.
Individuals who have one copy of the variant misplaced an extra 0.76 kilograms (1.7 kilos) over about eight months, whereas these with two copies of the variant misplaced about 1.5 kgs (3.3 kilos) greater than these with out the variant. That variant accounts for about 10 % of the distinction in weight reduction folks expertise on the medicine.
“It’s a small contribution to the burden distinction among the many sufferers, however it’s vital due to the importance of this gene,” says Andres Acosta, a doctor scientist on the Mayo Clinic in Rochester, Minn. Acosta was not concerned within the new examine however is a cofounder of Phenomix Sciences, an organization headquartered in Menlo Park, Calif., that gives AI-powered genetic assessments to predict which weight reduction drugs will work greatest for a affected person.
The identical genetic variant discovered to impression weight reduction additionally will increase the chance that somebody taking a GLP-1 drug will develop nausea and vomiting, the researchers found. That’s not at all times a nasty factor, Auton says. “In case you’re experiencing negative effects of nausea and vomiting, that will really be a signature that the remedy is having an impact.”
Folks taking tirzepatide, bought beneath the brand-name Zepbound, had been extra prone to have nausea and vomiting if that they had a particular variant of a special gene known as GIPR. The protein it makes is the goal of GIP, one other hormone concerned in blood sugar and urge for food management. The GIPR variant didn’t have a discernable impact on weight.
Not like semaglutide medicine Wegovy and Ozempic, tirzepatide targets each the GLP-1 and GIP receptors. And individuals who have variants in each the GLP1R and GIPR genes have practically 15 occasions elevated odds of vomiting when taking tirzepatide, the staff discovered.
Genetics alone doesn’t decide how effectively the medicine will work, Auton says. However understanding which variants an individual carries, he says, “could be fairly informative for people who’re contemplating these drugs. It might assist them put together themselves for the kind of expertise that they could have.”
